Factor XIa inhibition with asundexian after acute non-cardioembolic ischaemic stroke (PACIFIC-Stroke): an international, randomised, double-blind, placebo-controlled, phase 2b trial

Ashkan Shoamanesh(Population Health Research Institute), Robert G. Hart(University of British Columbia), Bodo Kirsch(Bayer (Germany)), Eric E. Smith(University of Calgary), Jaime Masjuán(Universidad de Alcalá), Pablo Colorado, Andrew M. Demchuk(University of Calgary), Robin Lemmens(VIB-KU Leuven Center for Microbiology), Valeria Caso, Jean‐Louis Mas(Centre Hospitalier Sainte-Anne), Hanne Christensen(Bispebjerg Hospital), Hardi Mundl(Roche (Switzerland)), László Csiba(University of Debrecen), Roland Veltkamp(Alfried Krupp Hospital), Thompson Robinson(University of Leicester), Alina Agafina(City Hospital No. 40), José M. Ferro(University of Lisbon), Christoph Neumann(Bayer (Germany)), Adam Stępień(National Academy of Medicine), Qiang Dong(Henan Normal University), Robert Mikulík(Tomas Bata University in Zlín), Gian Marco De Marchis(University of St.Gallen), Bruce Campbell(The Royal Melbourne Hospital), Arne Lindgren(Lund University), Stuart J. Connolly(Population Health Research Institute), Pooja Khatri(Yale University), Ivan Milanov(Vita-Salute San Raffaele University), Risto O. Roine(University of Turku), Stefan Greisenegger(Ludwig Boltzmann Institute Applied Diagnostics), Lizhen Xu(Hospital for Sick Children), Jonathan M. Coutinho(Amsterdam University Medical Centers), Teruyuki Hirano(The Graduate University for Advanced Studies, SOKENDAI), Peter Turčáni(University Hospital Bratislava), Laura Heenan(Population Health Research Institute)
The Lancet
September 1, 2022
Cited by 199


Related Papers